Statins for calcific aortic valve stenosis: into oblivion after SALTIRE and SEAS? An extensive review from bench to

Related Experiment Video

Updated: Jun 13, 2026

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro
05:47

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro

Published on: May 10, 2021

Hadewich Hermans, Paul Herijgers, Paul Holvoet

    Current Problems in Cardiology
    |May 11, 2010
    PubMed

    Insights

    Statins do not slow the progression of calcific aortic stenosis, despite similarities to atherosclerosis. Further research is needed to understand why these treatments are ineffective for this common heart valve disease.

    Area of Science:

    • Cardiology
    • Biomedical Engineering
    • Pathophysiology

    Background:

    • Calcific aortic stenosis is a prevalent heart valve disease, often necessitating valve replacement.
    • Historically viewed as passive wear, it's now understood as an active, inflammatory process akin to atherosclerosis.
    • Statins, widely used for cardiovascular prevention, were investigated for their potential to slow disease progression.

    Purpose of the Study:

    • To review the randomized trials SEAS and SALTIRE concerning statin efficacy in calcific aortic stenosis.
    • To explore the underlying pathophysiology of calcific aortic valve disease.
    • To hypothesize reasons for the lack of statin benefit and suggest future research directions.

    Main Methods:

    • Review of prospective randomized trials (SEAS, SALTIRE).
    • Analysis of preceding studies and basic science experiments.
    • Examination of key contributors to calcific aortic valve disease pathophysiology.

    Main Results:

    • Prospective randomized trials SEAS and SALTIRE did not demonstrate a benefit of statins in slowing calcific aortic stenosis progression.
    • Pre-clinical and non-randomized studies suggested potential efficacy, contrasting with definitive trial outcomes.

    Conclusions:

    • Statins are ineffective in modifying the course of calcific aortic stenosis.
    • The inflammatory and atherosclerotic-like mechanisms of the disease do not translate to statin responsiveness.
    • Further investigation is required to identify effective therapeutic targets for this condition.

    More Related Videos

    Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat04:30

    Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat

    Published on: February 4, 2021

    Related Concept Videos

    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
    Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

    Antianginal Drugs: Calcium Channel Blockers and Ranolazine

    Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
    CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
    Aortic Regurgitation III: Medical Management01:25

    Aortic Regurgitation III: Medical Management

    Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    Mitral Stenosis III: Medical Management01:26

    Mitral Stenosis III: Medical Management

    Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
    Coronary Artery Disease V: Interprofessional Care01:27

    Coronary Artery Disease V: Interprofessional Care

    Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...